GDC 0623

Drug Profile

GDC 0623

Alternative Names: GDC-0623; RG-7420

Latest Information Update: 09 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genentech
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 01 Aug 2014 Genetech completes a phase I trial in Solid tumours (Late-stage disease, Metastatic disease) in USA (NCT01106599)
  • 16 Mar 2012 Genentech is enrolling patients in its phase I trial for Solid tumours (metastatic, late-stage disease) in the USA (NCT01106599)
  • 30 Apr 2010 Phase-I clinical trials in Solid tumours (Metastatic, Late-stage disease) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top